Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation

NCT06533059 is registered in ClinicalTrials.gov with Alterome Therapeutics, Inc. as lead sponsor.

NCT NCT06533059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06533059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation
Lead sponsor
Alterome Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 22, 2024
Completion date
December 29, 2027
Enrollment
110 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, breast cancer, cancer, endometrial cancer, metastatic cancer